Two large Australian research groups have found CBD effective in treating bacterial diseases, of which include MRSA.
A two-week study showed that CBD was more effective than conventional antibiotics in penetrating a bacteria’s outer membrane and showed less tendency to cause resistance.
It gives hope for the treatment of gonorrhea in particular, which has shown resistance to conventional antibiotic treatment.
The findings mark the potential for a new class of antibiotic not seen for over 60 years.
Scientists at The University of Queensland, Australia have made a promising discovery in the search for an effective treatment against antibiotic-resistant disease using cannabidiol (CBD).
MRSA, legionnaires, meningitis, gonorrhea could be easier to treat following this groundbreaking discovery.
A collaborative study by the Centre for Superbug Solutions at the Institute for Molecular Bioscience based at the University of Queensland and Botanix Pharmaceuticals Limited discovered CBD’s potential during lab-controlled experiments.
CBD treating MRSA
The study imitated a patient’s treatment over a period of two weeks in order to find out how long the MRSA bacteria took to mutate and evade the CBD treatment. According to Associate Professor Mark Blaskovich, Director of the Centre for Superbug Solutions, the results are very encouraging.
“Cannabidiol (CBD) showed a low tendency to cause resistance in bacteria,” he reported. “Even when we sped up potential development by increasing concentrations of the antibiotic during ‘treatment’.
“These bacteria have an extra outer membrane,” he explains. “An additional line of defence that makes it harder for antibiotics to penetrate. This is the first time CBD has been shown to kill some types of Gram-negative bacteria”.
Treating Gonorrhea with CBD
The discovery specifically gives some hope for the treatment of gonorrhea, Australia’s second most common sexually-transmitted disease. Due to its various mutations, there is currently no single effective antibiotic treatment for the bacteria, which often presents very few (if any) symptoms in an infected person.
“This is particularly exciting because there have been no new molecular classes of antibiotics for Gram-negative infections discovered and approved since the 1960s”, said Professor Blaskovich. “We can now consider designing new analogs of CBD within improved properties.”
He attributes the success of the study to their close collaboration with Botanix Pharmaceuticals Limited, which provided the “formulation expertise” that aided the discovery of how CBD is delivered. President and Executive Chairman of Botanix, Vince Ippolito, praised their findings.
“Congratulations to Dr. Blaskovich and his team for producing this significant body of research”, said Ippolito. “The published data clearly establishes the potential of synthetic cannabinoids as antimicrobials.”